Preventive effect of trimetazidine on contrast - induced nephropathy in patients with chronic renal insufficiency after coronary intervention / 实用医学杂志
The Journal of Practical Medicine
; (24): 2558-2562, 2017.
Article
em Zh
| WPRIM
| ID: wpr-611894
Biblioteca responsável:
WPRO
ABSTRACT
Objective This study was to investigate the role of trimetazidine in the prevention of contrast-induced nephropathy (CIN) in renal dysfunction patients undergoing coronary angiography. Methods A total of 151 patients with renal dysfunction who underwent coronary angiography were enrolled in our study and randomly divided into control group (n=77) and trimetazidine group (n=74). Standard hydration was administered in all the patients. In trimetazidine group, patients were administered trimetazidine orally for 48 hours before and 7 days after coronary angiography. Adverse events were observed in 12 months. Results (1) For 24 h and 48 h after the procedure:levels of SCr and CysC in the control group were significantly increased compared with baseline levels; levels of SCr and CysC in trimetazidine group were not increased, compared with baseline levels;levels of SCr and CysC were lower in trimetazidine group than the control group. (2)The incidence of CIN was reduced in trimetazidine group compared with control group (22.1%vs 9.5%,P=0.034). (3) Kaplan-Meier analysis showed that the incidence of adverse events in trimetazidine group was lower compared with the control group (P = 0.003). Conclusions Trimetazidine in combination with standard hydration is more effective than isotonic saline alone in protecting renal function in patients with renal dysfunction who undergo coronary angiography.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
The Journal of Practical Medicine
Ano de publicação:
2017
Tipo de documento:
Article